Nevada Accuses Juul of Targeting Youth in Lawsuit

Dec.08.2022
Nevada Accuses Juul of Targeting Youth in Lawsuit
Juul accused of marketing to minors and deceiving consumers on nicotine content in Nevada civil suit.

The Nevada Attorney General's office has accused electronic cigarette manufacturer Juul of following the playbook of "big tobacco companies," attempting to make their products attractive to minors and deceiving consumers about the nicotine content in their devices.


In a civil lawsuit filed on Tuesday, the state claimed that Juul Labs, Inc. of San Francisco has hindered the state government's efforts to ban the sale of most flavored cigarettes and market products to people under the age of 21, which was implemented by Congress in the 1990s and later.


State officials said in the lawsuit, "Thanks to the joint efforts of states, the federal government, public health advocates, and many others, the smoking rates among youth and adults have decreased significantly. Unfortunately, the emergence of e-cigarettes has reversed much of the progress.


The complaint was filed after Nevada had reached an agreement with Juul Labs in September, as one of 32 states to settle with the company for $438 million. Nevada's portion of the settlement amounted to $14.4 million. Juul also agreed to stop advertising its electronic cigarettes to minors and to cease using sponsorships and social media influencers to promote its products.


An appeal has been filed with the Clark County District Court in Las Vegas, requesting a permanent injunction to prevent Juul Labs from engaging in violations of Nevada's Deceptive Trade Practices Act. The appeal also calls for civil penalties to be imposed for each infraction committed by the company and urges consideration for compensation and refunds.


A spokesperson for Juul, Arik Ben-Zvi, said that Nevada's application does not constitute a new complaint against the company, but is related to a multi-state settlement agreement reached in September, which includes Nevada.


He stated, "The terms of the agreement align with our current business practices that were established since the company-wide restructuring in autumn 2019.


The US Food and Drug Administration banned the sale of Juul products in June, but suspended its decision after Juul appealed, awaiting a review of further "scientific" issues.


In a complaint filed this week, officials in Nevada compared the e-cigarette industry to the "big tobacco" companies of the pre-1990s, when companies "realized that increasing cigarette sales depended to a large extent on getting individuals addicted to their products from a young age.


As a result, major tobacco companies have developed a comprehensive plan to attract vulnerable children and entice them to use their products,” the office stated. “They have also spent significant resources to expose young people to tobacco imagery through magazine ads, sporting events, and billboards.


Juul Labs sells electronic cigarettes using its proprietary product called a "pod," which delivers nicotine to the users inhaling the e-cigarette.


The pods of the company contain significantly more nicotine compared to other brands and include "nicotine salts" pioneered by Juul Labs, making the inhalant smoother and less irritating than earlier types of electronic smoking devices, according to national officials.


The Office of the Attorney General stated that the company, in its marketing efforts, misled consumers into believing that its products were either nicotine-free or had a lower nicotine concentration and were a safer alternative to combustible cigarettes.


According to state officials, Juul Labs has been selling its tobacco devices to minors from the beginning and, in fact, "the main driver of its explosive growth is young people adopting its products.


A complaint alleges that the company has focused marketing efforts on Instagram, Twitter, Facebook and other social media channels to target younger users.


2FIRSTS will continue to follow and report on this topic. Further updates will be available on the "2FIRSTS APP". Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

South Korea Constitutional Court Upholds Volume-Based E-Liquid Tax, With Challenged Rates at KRW 370 and KRW 628 per Milliliter
South Korea Constitutional Court Upholds Volume-Based E-Liquid Tax, With Challenged Rates at KRW 370 and KRW 628 per Milliliter
South Korea's Constitutional Court has upheld fixed taxes on nicotine-containing e-cigarette liquids based on solution volume, ruling that challenged provisions imposing KRW 370 per milliliter in individual consumption tax and KRW 628 per milliliter in tobacco consumption tax do not violate the Constitution. The cases stemmed from historical disputes involving importers that reported nicotine as being extracted from tobacco stems rather than leaves. South Korea has since broadened its tobacco definition to include synthetic nicotine, while current tax laws provide reduced rates for certain products not derived from tobacco.
Sep.18
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives
How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How are investors reassessing the global tobacco industry as nicotine markets evolve? In an interview with 2Firsts, Charlie Chen, Head of Research at CCB International Securities, forecasts annual growth of 30–50% for nicotine pouches, outpacing vaping and heated tobacco. He examines how regulatory enforcement, shifting market shares and new business models are influencing company valuations. The report also explores differences between multinational tobacco groups and Chinese companies, drawing on insights from the New Approaches Summit on profitability, investment strategies and industry consolidation.
Nov.11
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives